← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Tumor necrosis factor alpha (TNF-alpha) inhibitors
certolizumab pegol
L04AB05
Forms & Strengths
- Prefilled syringe: 200mg/mL
- Lyophilized powder: 200mg/vial
- Prefilled pen: 200mg/mL
Adult Dosing
- Initial dose: 400mg SC at weeks 0, 2, 4
- Maintenance dose: 200mg SC every 2 weeks
- Alternative maintenance dose: 400mg SC every 4 weeks
Pediatric Dosing
- Juvenile idiopathic arthritis: 20-40 kg, 200-400mg/m² SC every 2 weeks
- Not recommended for children under 2 years or less than 20 kg
Indications
- Moderate to severe Crohn's disease
- Moderate to severe rheumatoid arthritis
- Active psoriatic arthritis
- Ankylosing spondylitis
- Moderate to severe plaque psoriasis
Mechanism of Action
- TNF-alpha inhibitor
- Binds to human TNF-alpha with high affinity
- Prevents interaction with TNF-alpha receptors on cell surfaces
Contraindications
- Hypersensitivity to certolizumab pegol
- Active tuberculosis
- Severe infections (e.g. sepsis, opportunistic infections)
- Congestive heart failure (NYHA III/IV)
Adverse Reactions
- Upper respiratory tract infections
- Headache
- Injection site reactions
- Abdominal pain
- Increased risk of serious infections (e.g. TB, invasive fungal infections)
Drug Interactions
- Anakinra: increased risk of serious infections
- Abatacept: increased risk of serious infections
- Live vaccines: avoid use due to increased risk of infections
- Immunosuppressants (e.g. cyclosporine, theophylline): use with caution
Curated Content: Needs Vetting Before Put to Clinical Use